IL128900A0 - Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor - Google Patents
Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitorInfo
- Publication number
- IL128900A0 IL128900A0 IL12890097A IL12890097A IL128900A0 IL 128900 A0 IL128900 A0 IL 128900A0 IL 12890097 A IL12890097 A IL 12890097A IL 12890097 A IL12890097 A IL 12890097A IL 128900 A0 IL128900 A0 IL 128900A0
- Authority
- IL
- Israel
- Prior art keywords
- beta
- matrix metalloproteinases
- hydroxamic acids
- sulfonyl hydroxamic
- metalloproteinases inhibitor
- Prior art date
Links
- 229940124761 MMP inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Lubricants (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2684896P | 1996-09-27 | 1996-09-27 | |
PCT/US1997/016348 WO1998013340A1 (en) | 1996-09-27 | 1997-09-19 | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
IL128900A0 true IL128900A0 (en) | 2000-01-31 |
Family
ID=21834136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12890097A IL128900A0 (en) | 1996-09-27 | 1997-09-19 | Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor |
Country Status (22)
Country | Link |
---|---|
US (2) | US5847153A (pt) |
EP (1) | EP0929519B1 (pt) |
JP (1) | JP2001516338A (pt) |
KR (1) | KR20000048639A (pt) |
CN (1) | CN1158254C (pt) |
AT (1) | ATE289590T1 (pt) |
AU (1) | AU726799B2 (pt) |
BR (1) | BR9712134A (pt) |
CA (1) | CA2266368A1 (pt) |
CZ (1) | CZ92399A3 (pt) |
DE (1) | DE69732571T2 (pt) |
EA (1) | EA001460B1 (pt) |
ES (1) | ES2236829T3 (pt) |
HK (1) | HK1022468A1 (pt) |
HU (1) | HUP0000145A3 (pt) |
ID (1) | ID21897A (pt) |
IL (1) | IL128900A0 (pt) |
NO (1) | NO312893B1 (pt) |
NZ (1) | NZ334729A (pt) |
PL (1) | PL332509A1 (pt) |
UA (1) | UA48262C2 (pt) |
WO (1) | WO1998013340A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000517297A (ja) * | 1996-08-07 | 2000-12-26 | ダーウィン・ディスカバリー・リミテッド | Mmpとtnfの抑制活性を有するヒドロキサム酸誘導体およびカルボン酸誘導体 |
US6566384B1 (en) * | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
WO1998013340A1 (en) | 1996-09-27 | 1998-04-02 | Pharmacia & Upjohn Company | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS |
AU5337498A (en) | 1997-01-22 | 1998-08-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted beta-thiocarboxylic acids |
GB9702088D0 (en) | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
US6172057B1 (en) | 1997-02-27 | 2001-01-09 | American Cyanamid Company | N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
PL335732A1 (en) * | 1997-03-04 | 2000-05-08 | Monsanto Co | Sulphonyl hydroxamic acids with bivalent aryl or heteroaryl ring |
US6362183B1 (en) | 1997-03-04 | 2002-03-26 | G. D. Searle & Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
US6187924B1 (en) * | 1997-11-12 | 2001-02-13 | Darwin Discovery, Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
US6063786A (en) * | 1997-11-12 | 2000-05-16 | Darwin Discovery, Ltd. | Heterocyclic compounds having MMP and TNF inhibitory activity |
PT1037868E (pt) * | 1997-11-21 | 2003-06-30 | Upjohn Co | Derivados alfa-hidroxi amino e halo de acidos beta-sulfonil-hidroxamicos como inibidores de metaloproteinases matriciais |
CA2317455C (en) * | 1998-01-30 | 2011-01-25 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
ES2310636T3 (es) | 1998-06-18 | 2009-01-16 | F. Hoffmann-La Roche Ag | Proceso para sulfuros de arilalquilo. |
GB9916562D0 (en) | 1999-07-14 | 1999-09-15 | Pharmacia & Upjohn Spa | 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora |
US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
GB0017435D0 (en) * | 2000-07-14 | 2000-08-30 | Pharmacia & Upjohn Spa | 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
CA2632030A1 (en) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
EP2081905B1 (en) | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
JP5030114B2 (ja) | 2006-09-25 | 2012-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体をモジュレートする化合物 |
JP5492092B2 (ja) * | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
CA2730037A1 (en) * | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
CA2737639A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US8383615B2 (en) | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
US8383651B2 (en) * | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB689608A (en) * | 1950-04-13 | 1953-04-01 | Basf Ag | Improvements in the production of gamma-sulphonyl carboxylic acids |
US2659752A (en) * | 1951-08-09 | 1953-11-17 | Goodrich Co B F | Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof |
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
WO1993020047A1 (en) * | 1992-04-07 | 1993-10-14 | British Bio-Technology Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
DE4233099A1 (de) * | 1992-10-01 | 1994-04-07 | Hoechst Ag | Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren |
DE4233100A1 (de) * | 1992-10-01 | 1994-04-07 | Hoechst Ag | Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte |
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
EP0640594A1 (en) * | 1993-08-23 | 1995-03-01 | Fujirebio Inc. | Hydantoin derivative as metalloprotease inhibitor |
GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
EP0780386B1 (en) * | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
DE69728375T2 (de) * | 1996-01-02 | 2005-02-10 | Aventis Pharmaceuticals Inc. | Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen |
TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
WO1998013340A1 (en) * | 1996-09-27 | 1998-04-02 | Pharmacia & Upjohn Company | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS |
US6362183B1 (en) | 1997-03-04 | 2002-03-26 | G. D. Searle & Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
-
1997
- 1997-09-19 WO PCT/US1997/016348 patent/WO1998013340A1/en not_active Application Discontinuation
- 1997-09-19 ID IDW990118A patent/ID21897A/id unknown
- 1997-09-19 AT AT97945207T patent/ATE289590T1/de not_active IP Right Cessation
- 1997-09-19 DE DE69732571T patent/DE69732571T2/de not_active Expired - Fee Related
- 1997-09-19 EA EA199900332A patent/EA001460B1/ru not_active IP Right Cessation
- 1997-09-19 NZ NZ334729A patent/NZ334729A/xx unknown
- 1997-09-19 CN CNB971979227A patent/CN1158254C/zh not_active Expired - Fee Related
- 1997-09-19 CZ CZ99923A patent/CZ92399A3/cs unknown
- 1997-09-19 PL PL97332509A patent/PL332509A1/xx unknown
- 1997-09-19 UA UA99042348A patent/UA48262C2/uk unknown
- 1997-09-19 KR KR1019990702581A patent/KR20000048639A/ko not_active Application Discontinuation
- 1997-09-19 US US08/934,408 patent/US5847153A/en not_active Expired - Fee Related
- 1997-09-19 BR BR9712134-7A patent/BR9712134A/pt active Search and Examination
- 1997-09-19 EP EP97945207A patent/EP0929519B1/en not_active Expired - Lifetime
- 1997-09-19 US US09/269,185 patent/US6235928B1/en not_active Expired - Fee Related
- 1997-09-19 HU HU0000145A patent/HUP0000145A3/hu unknown
- 1997-09-19 AU AU46459/97A patent/AU726799B2/en not_active Ceased
- 1997-09-19 ES ES97945207T patent/ES2236829T3/es not_active Expired - Lifetime
- 1997-09-19 JP JP51570298A patent/JP2001516338A/ja not_active Withdrawn
- 1997-09-19 IL IL12890097A patent/IL128900A0/xx unknown
- 1997-09-19 CA CA002266368A patent/CA2266368A1/en not_active Abandoned
-
1999
- 1999-03-26 NO NO19991494A patent/NO312893B1/no unknown
-
2000
- 2000-02-14 HK HK00100870A patent/HK1022468A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUP0000145A2 (en) | 2000-07-28 |
NO991494D0 (no) | 1999-03-26 |
NO991494L (no) | 1999-05-26 |
ATE289590T1 (de) | 2005-03-15 |
EP0929519B1 (en) | 2005-02-23 |
DE69732571D1 (de) | 2005-03-31 |
CZ92399A3 (cs) | 1999-07-14 |
DE69732571T2 (de) | 2006-01-12 |
US6235928B1 (en) | 2001-05-22 |
EP0929519A1 (en) | 1999-07-21 |
CN1158254C (zh) | 2004-07-21 |
WO1998013340A1 (en) | 1998-04-02 |
US5847153A (en) | 1998-12-08 |
ES2236829T3 (es) | 2005-07-16 |
JP2001516338A (ja) | 2001-09-25 |
AU4645997A (en) | 1998-04-17 |
NZ334729A (en) | 2001-01-26 |
EA001460B1 (ru) | 2001-04-23 |
HUP0000145A3 (en) | 2001-12-28 |
UA48262C2 (uk) | 2002-08-15 |
NO312893B1 (no) | 2002-07-15 |
CN1230177A (zh) | 1999-09-29 |
PL332509A1 (en) | 1999-09-13 |
BR9712134A (pt) | 1999-08-31 |
KR20000048639A (ko) | 2000-07-25 |
AU726799B2 (en) | 2000-11-23 |
HK1022468A1 (en) | 2000-08-11 |
ID21897A (id) | 1999-08-05 |
EA199900332A1 (ru) | 1999-12-29 |
CA2266368A1 (en) | 1998-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL128900A0 (en) | Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitor | |
IL143545A0 (en) | Thrombin inhibitors | |
CA2367017A1 (en) | Inhibitors of impdh enzyme | |
GR3035181T3 (en) | Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors | |
ES2052452A1 (es) | Procedimiento de preparacion de inhibidores duales de no-sintasa y ciclooxigenasa. | |
NO20003018L (no) | Triazinangiogenese-inhibitorer | |
NZ237023A (en) | 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions | |
EA200100804A1 (ru) | Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз | |
UA37181C2 (uk) | ГІДРОХЛОРИД 7-<font face="Symbol">b</font>-[(Z)-2-(2-АМІНО-4-ТІАЗОЛІЛ)-3-ГІДРОКСИІМІНОАЦЕТА- МІДО]-3-(1,2,3-ТРИАЗОЛ-4-ІЛ)ТІОМЕТИЛТІО-3-ЦЕФЕМ-4-КАРБОНОВОЇ КИСЛОТИ АБО ЙОГО ГІДРАТИ, ЩО МАЮТЬ АНТИБАКТЕРІАЛЬНУ ДІЮ, ФАРМАЦЕВТИЧНА АНТИБАКТЕРІАЛЬНА КОМПОЗИЦІЯ, СПОСІБ ПРИГНІЧЕННЯ РОЗВИТКУ БАКТЕРІЙ, СПОСІБ ЛІКУВАННЯ БАКТЕРІАЛЬНИХ ІНФЕКЦІЙ | |
EA200101085A1 (ru) | Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз | |
CO5261493A1 (es) | Procedimiento y compuestos para la inhibicion de la mrp1 | |
GB9715030D0 (en) | Metalloproteinase inhibitors | |
AU5090393A (en) | Platelet aggregation inhibitors | |
TR200003252T2 (tr) | Interleukın-1ß dönüştürme enzimi succınamıde inhibitörleri. | |
CA2266759A1 (en) | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | |
AU5710696A (en) | Platelet aggregation inhibitors | |
NO983511L (no) | Difenylstilbener som pro-legemidler til COX-2-inhibitorer | |
HUP0301010A2 (hu) | A koleszteril-észter és a viaszészter szintézisét egyaránt gátló vegyületek faggyúmirigy-betegségek kezeléséhez és ezeket tartalmazó gyógyszerkészítmények | |
ES2147499A1 (es) | Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos. |